Literature DB >> 24480915

Causes of pulmonary hypertension in the elderly.

Meredith E Pugh1, Lakshmi Sivarajan2, Li Wang3, Ivan M Robbins4, John H Newman4, Anna R Hemnes4.   

Abstract

BACKGROUND: Pulmonary hypertension (PH) is common in elderly patients, but a detailed analysis of the causes of PH in the elderly has not been performed. We hypothesized that pulmonary arterial hypertension (PAH) is rare in elderly patients and sought to describe the characteristics of these patients at a large referral center.
METHODS: Clinical and hemodynamic data were collected on consecutive patients ≥ 65 years of age referred for evaluation of PH. The subtype of PH was determined after standard evaluation using the World Health Organization (WHO) classification. Patients with PH not meeting criteria for PAH with "out-of-proportion" PH related to group 2 or group 3 disease were classified as "other/mixed PH." A model using age, presence of connective tissue disease, and left atrial size was developed to predict the probability of PAH diagnosis.
RESULTS: Two hundred forty-six elderly patients were evaluated (mean age, 72.9 ± 5.5 years, 78% women); 36 had PAH (15%). Idiopathic PAH was rare (four patients, 1.6%). WHO group 2 PH was the most frequent diagnosis (n = 70, 28% of cohort); mixed/other PH (n = 43, 17%) and WHO group 3 PH (n = 34, 14%) were also common diagnoses. Connective tissue disease strongly predicted PAH diagnosis (OR, 27.2; 95% CI, 9.5-77.6).
CONCLUSIONS: PAH is an uncommon cause of PH in elderly patients, most frequently associated with connective tissue disease. WHO group 2 PH and mixed disease are common, highlighting a need for careful phenotyping of elderly patients with PH prior to initiating PAH therapy.

Entities:  

Mesh:

Year:  2014        PMID: 24480915      PMCID: PMC4077408          DOI: 10.1378/chest.13-1900

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  20 in total

1.  Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management.

Authors:  Shelley Shapiro; Glenna L Traiger; Michelle Turner; Michael D McGoon; Prieya Wason; Robyn J Barst
Journal:  Chest       Date:  2011-07-14       Impact factor: 9.410

2.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

Review 3.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

Review 4.  Diagnosis and assessment of pulmonary arterial hypertension.

Authors:  David B Badesch; Hunter C Champion; Miguel Angel Gomez Sanchez; Marius M Hoeper; James E Loyd; Alessandra Manes; Michael McGoon; Robert Naeije; Horst Olschewski; Ronald J Oudiz; Adam Torbicki
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

5.  Guidelines for the diagnosis and treatment of pulmonary hypertension.

Authors:  N Galiè; M M Hoeper; M Humbert; A Torbicki; J-L Vachiery; J A Barbera; M Beghetti; P Corris; S Gaine; J S Gibbs; M A Gomez-Sanchez; G Jondeau; W Klepetko; C Opitz; A Peacock; L Rubin; M Zellweger; G Simonneau
Journal:  Eur Respir J       Date:  2009-09-12       Impact factor: 16.671

6.  Unexplained pulmonary hypertension in elderly patients.

Authors:  Brian P Shapiro; Michael D McGoon; Margaret M Redfield
Journal:  Chest       Date:  2007-01       Impact factor: 9.410

7.  Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction.

Authors:  Thenappan Thenappan; Sanjiv J Shah; Mardi Gomberg-Maitland; Brett Collander; Ajay Vallakati; Pranavkumar Shroff; Stuart Rich
Journal:  Circ Heart Fail       Date:  2011-03-16       Impact factor: 8.790

8.  The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries.

Authors:  Adaani E Frost; David B Badesch; Robyn J Barst; Raymond L Benza; C Gregory Elliott; Harrison W Farber; Abby Krichman; Theodore G Liou; Gary E Raskob; Prieya Wason; Kathleen Feldkircher; Michelle Turner; Michael D McGoon
Journal:  Chest       Date:  2010-06-17       Impact factor: 9.410

9.  Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.

Authors:  David B Badesch; Gary E Raskob; C Greg Elliott; Abby M Krichman; Harrison W Farber; Adaani E Frost; Robyn J Barst; Raymond L Benza; Theodore G Liou; Michelle Turner; Scott Giles; Kathy Feldkircher; Dave P Miller; Michael D McGoon
Journal:  Chest       Date:  2009-10-16       Impact factor: 9.410

10.  Association of the metabolic syndrome with pulmonary venous hypertension.

Authors:  Ivan M Robbins; John H Newman; Roger F Johnson; Anna R Hemnes; Richard D Fremont; Robert N Piana; David X Zhao; Daniel W Byrne
Journal:  Chest       Date:  2009-02-02       Impact factor: 9.410

View more
  23 in total

1.  Pulmonary arterial hypertension in the elderly: Clinical perspectives.

Authors:  Nicholas Rothbard; Abhinav Agrawal; Conrad Fischer; Arunabh Talwar; Sonu Sahni
Journal:  Cardiol J       Date:  2018-08-29       Impact factor: 2.737

2.  Pulmonary arterial hypertension treatment guidelines: new answers and even more questions.

Authors:  Anna R Hemnes
Journal:  Chest       Date:  2014-08       Impact factor: 9.410

3.  Mortality in US veterans with pulmonary hypertension: a retrospective analysis of survival by subtype and baseline factors.

Authors:  Aaron W Trammell; Amit J Shah; Lawrence S Phillips; C Michael Hart
Journal:  Pulm Circ       Date:  2019 Jan-Mar       Impact factor: 3.017

Review 4.  Endothelial Senescence: A New Age in Pulmonary Hypertension.

Authors:  Miranda K Culley; Stephen Y Chan
Journal:  Circ Res       Date:  2022-03-17       Impact factor: 17.367

Review 5.  Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults.

Authors:  Yasushi Tsujimoto; Junji Kumasawa; Sayaka Shimizu; Yoshio Nakano; Yuki Kataoka; Hiraku Tsujimoto; Michihiko Kono; Shinji Okabayashi; Haruki Imura; Takahiro Mizuta
Journal:  Cochrane Database Syst Rev       Date:  2022-05-09

6.  Features Associated With Discordance Between Pulmonary Arterial Wedge Pressure and Left Ventricular End Diastolic Pressure in Clinical Practice: Implications for Pulmonary Hypertension Classification.

Authors:  Anna R Hemnes; Alexander R Opotowsky; Tufik R Assad; Meng Xu; Laura N Doss; Eric Farber-Eger; Quinn S Wells; Evan L Brittain
Journal:  Chest       Date:  2018-08-24       Impact factor: 9.410

7.  Effect of Age on Phenotype and Outcomes in Pulmonary Arterial Hypertension Trials.

Authors:  Jonathan A Rose; Jody M Cleveland; Youlan Rao; Omar A Minai; Adriano R Tonelli
Journal:  Chest       Date:  2016-01-13       Impact factor: 9.410

8.  Sex Differences in Ischemic Stroke Outcomes in Patients With Pulmonary Hypertension.

Authors:  Tiberiu A Pana; Dana K Dawson; Mohamed O Mohamed; Fiona Murray; David L Fischman; Michael P Savage; Mamas A Mamas; Phyo K Myint
Journal:  J Am Heart Assoc       Date:  2021-03-08       Impact factor: 5.501

Review 9.  Pulmonary hypertension in the elderly: a different disease?

Authors:  Grégory Berra; Stéphane Noble; Paola M Soccal; Maurice Beghetti; Frédéric Lador
Journal:  Breathe (Sheff)       Date:  2016-03

10.  Prognostic Factors in Patients With Pulmonary Hypertension-A Nationwide Cohort Study.

Authors:  Wei-Ting Chang; Shih-Feng Weng; Chih-Hsin Hsu; Jhih-Yuan Shih; Jhi-Joung Wang; Chun-Ying Wu; Zhih-Cherng Chen
Journal:  J Am Heart Assoc       Date:  2016-08-29       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.